13 stories mentioning TXGUpdated just now
Every FINWIRES story that references TXG, newest first.
Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.
Shehnaaz Suliman, Director, on September 22, 2026, sold 5,723 shares in 10x Genomics (TXG) for $464,668. Following the Form 4 filing with the SEC, Suliman has control over a total of 23,792 Class A common shares of the company, with 23,792 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1770787/000161071726000422/xslF345X05/form4.xml
Adam Taich, Chief Financial Officer, on September 09, 2026, sold 46,388 shares in 10x Genomics (TXG) for $2,995,470. Following the Form 4 filing with the SEC, Taich has control over a total of 316,344 Class A common shares of the company, with 316,344 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1770787/000161071726000414/xslF345X05/form4.xml
10x Genomics (TXG) is incorporating medical artificial intelligence software company Lunit's AI-powered pathology platform, Lunit SCOPE IO, into its oncology biomarker discovery workflow, Lunit said Thursday.The platform adds the ability to analyze Hematoxylin and Eosin pathology images alongside spatial molecular data generated from 10x's oncology-focused clinical research studies, according to a statement.Financial terms of the collaboration were not provided.Price: $66.27, Change: $-1.02, Percent Change: -1.52%
John R Stuelpnagel, Director, on September 03, 2026, sold 20,000 shares in 10x Genomics (TXG) for $1,235,072. Following the Form 4 filing with the SEC, Stuelpnagel has control over a total of 328,436 Class A common shares of the company, with 328,436 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1770787/000161071726000405/xslF345X05/form4.xml
10x Genomics (TXG) is offering a compelling product cycle but its two franchises are pulling in opposite directions, RBC Capital Markets said in a note Tuesday."Spatial and single cell represent two opposing forces in the growth mosaic," the report said.The company is a leader in high-plex spatial molecular profiling, enabling researchers to map gene and protein expression within intact tissue, the note said. It has over 60% market share.The spatial business is still relatively early in adoption and has been growing at a double-digit rate, even before the upcoming Atera launch, the note said.But single-cell remains a structural growth dampener, with double-digit declines in price-per-reaction for single cell offset by a double-digit growth in reaction volume, the report said."We're forecasting only flattish performance for 10x's single cell business over the next five years, meaningfully dilutive to the overall growth algorithm," it said.RBC started coverage with a sector perform rating, saying that it could become more constructive on the stock if the single-cell franchise could return to "meaningful" growth.Price: $61.36, Change: $-1.10, Percent Change: -1.75%
10x Genomics (TXG) has an average rating of overweight and mean price target of $51, according to analysts polled by FactSet.
Healthcare stocks were lower late Friday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each shedding about 0.4%.The iShares Biotechnology ETF (IBB) fell 2.7%.In corporate news, BioNTech (BNTX) said it terminated its phase 2 trial evaluating autogene cevumeran as an adjuvant monotherapy in people with colorectal cancer. The trial's independent safety board recommended discontinuing treatment and ending the trial, as further continuation was unlikely to change the efficacy outcome, the company said. Shares fell 8%.Eli Lilly (LLY) said the US Food and Drug Administration approved Mounjaro to lower the risk of major adverse cardiovascular events in adults with type 2 diabetes who are at high risk for those events. Lilly shares were down 0.9%.10x Genomics (TXG) said a Delaware federal jury awarded the company more than $4.8 million after finding that three patents held through its Scale Biosciences unit were infringed by Parse Biosciences, a subsidiary of Qiagen (QGEN). 10x Genomics shares were down 5.2%, and Qiagen was shedding 1.3%.Quoin Pharmaceuticals (QNRX) reported "positive" interim data from its ongoing phase 2/3 study of QRX003 in patients with netherton syndrome, and also a private placement financing of up to $50.0 million. Shares surged 18%.
Healthcare stocks were lower late Friday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each shedding 0.4%.The iShares Biotechnology ETF (IBB) dropped 2.7%.In corporate news, 10x Genomics (TXG) said a Delaware federal jury awarded the company more than $4.8 million after finding that three patents held through its Scale Biosciences unit were infringed by Parse Biosciences, a subsidiary of Qiagen (QGEN). 10x Genomics shares were down 5.2%, and Qiagen was shedding 1.3%.
10x Genomics (TXG) said a Delaware federal jury awarded the company more than $4.8 million after finding that three patents held through its Scale Biosciences unit were infringed by Parse Biosciences, a subsidiary of Qiagen (QGEN).The jury also rejected Parse's challenges to the patents' validity, confirming all three as valid and enforceable, 10x said Friday in a statement.The damages reflect a 14% royalty on sales of Parse's Evercode Whole Transcriptome products from 2021 through mid-2026, 10x said.10x plans to pursue additional remedies in post-trial proceedings, including enhanced damages, attorneys' fees and a permanent injunction against further infringement by Parse in the US.Qiagen didn't immediately reply to a request for comment from.10x shares fell 5.4% in Friday trading, and Qiagen dropped 1.3%.Price: $61.33, Change: $-3.52, Percent Change: -5.43%
Sarah A. Teichmann, Director, on August 13, 2026, sold 7,551 shares in 10x Genomics (TXG) for $432,279. Following the Form 4 filing with the SEC, Teichmann has control over a total of 28,058 Class A common shares of the company, with 28,058 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1770787/000161071726000359/xslF345X05/form4.xml
John R Stuelpnagel, Director, on August 11, 2026, sold 20,000 shares in 10x Genomics (TXG) for $1,155,055. Following the Form 4 filing with the SEC, Stuelpnagel has control over a total of 348,436 Class A common shares of the company, with 348,436 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1770787/000161071726000358/xslF345X05/form4.xml
10x Genomics (TXG) has an average rating of overweight and mean price target of $25.77, according to analysts polled by FactSet.Price: $43.00, Change: $+0.27, Percent Change: +0.63%
Serge Saxonov, Director, Chief Executive Officer, on June 22, 2026, sold 30,000 shares in 10x Genomics (TXG) for $1,033,269. Following the Form 4 filing with the SEC, Saxonov has control over a total of 1,393,301 Class A common shares of the company, with 1,108,380 shares held directly and 284,921 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1770787/000161071726000293/xslF345X05/form4.xml
